Citations

Showing 10 of 108152 citations.

Favorable Functional Recovery in Severe Traumatic Brain Injury Survivors beyond Six Months
Wilkins, Tiffany, Beers, Sue R. , Borrasso, Allison J., Brooks, Jordan, Mesley, Matthew, Puffer, Ross C. , Chang, Yue‐Fang , Okonkwo, David O. , Puccio, Ava M. , Puffer, Ross

Mayo Clinic

Journal of Neurotrauma | June 18, 2019 | Volume: 36 | Issue: 22 | Pages: 3158-3163

10.1089/neu.2018.6153 | PMID 31210093 Get It

Favorable long-term functional outcomes after severe traumatic brain injury (TBI) may be underestimated. We analyzed 24-month functional outcomes from a consecutive series of severe TBI survivors. A prospective, observational database of severe TBI survivors from a single institution was analyzed. Glasgow Outcome Scale-Extended (GOS-E) scores were obtained at 3, 6, 12, and 24 months post-injury. GOS-E scores were dichotomized into unfavorable and favorable outcomes, and the proportion of survivors changing from unfavorable to favorable outcomes was calculated using Wilcoxon signed-rank tests. Surviving adults ( N = 304; mean age ± standard deviation = 35.06 ± 15.11; 80.92% male; mode of initial GCS = 7) were analyzed. A statistically significant mean increase in GOS-E was noted from 3 to 6, 6 to 12, 12 to 24, and 6 to 24 months after injury (0.65 [ p < 0.0001], 0.42 [ p < 0.0001], 0.23 [ p = 0.020], and 0.61 [ p < 0.0001], respectively). Moreover, 43% of survivors from 3 to 6 months, 36% from 6 to 12 months, 38% from 12 to 24 months, and 54% from 6 to 24 months progressed from an unfavorable to a favorable outcome. Two thirds of survivors in the unfavorable category at 3 months had favorable outcomes at 2 years. Overall, 74% of surviving adults with a documented GOS-E at 2 years after injury had a favorable outcome. Severe TBI survivors demonstrated significant improvement in functional outcomes from 3 to 24 months after injury. At 2 years, three fourths of survivors had a favorable outcome. Long-term prognosis in severe TBI is better than broadly appreciated.
Utility of the Movement Disorders Society Criteria for Progressive Supranuclear Palsy in Clinical Practice
Ali, Farwa , Botha, Hugo , Whitwell, Jennifer L. , Josephs, Keith A. , Botha, Hugo

Mayo Clinic

Movement Disorders Clinical Practice | June 18, 2019 | Volume: 6 | Issue: 6 | Pages: 436-439

10.1002/mdc3.12807 | PMID 31392243 Get It

ABSTRACTObjectivesWhen the 2017 Movement Disorders Society Criteria for progressive supranuclear palsy is applied, patients may appear to have multiple phenotypes. The maximum allocation extinction rules were developed to provide a consistent method for applying the criteria and reaching a single diagnostic label. In this study, we apply both to a neuropathologic cohort of progressive supranuclear palsy and other parkinsonian conditions.MethodsAn autopsy cohort of 54 patients with progressive supranuclear palsy and 56 patients with other neuropathologic diseases was selected. Clinical data were retrospectively abstracted, and the diagnostic criteria for progressive supranuclear palsy were applied. All possible phenotypes applicable were listed and maximum allocation extinction rules were applied to assess reduction in the number of phenotypes ascribed per patient.ResultsIn the progressive supranuclear palsy group, 52 patients met the criteria for multiple phenotypes, with an average of 7 phenotypes per patient. In the nonprogressive supranuclear palsy group, all 56 patients had features of more than one phenotype, up to 3 per patient. After application of maximum allocation extinction rules, the majority of the patients in both groups had a single predominant phenotype. Freezing of gait, supranuclear gaze palsy, and frontal behavioral syndrome were more common in the progressive supranuclear palsy group.ConclusionsThe diagnostic criteria for progressive supranuclear palsy identify many clinical features, thereby leading to assignment of multiple phenotypes per patient. We demonstrate that the maximum allocation extinction rules can effectively lead to a single consensus phenotype, maintaining a uniform diagnostic label for clinical and research applications.
Echocardiographic mimicker of thrombus on a mechanical aortic valve prosthesis due to cavitation: A paradoxical phenomenon of pressure recovery
Wang, Zhenzhen , Ayoub, Chadi , Thaden, Jeremy J. , Miller, Fletcher A., Sinak, Lawrence J., Rihal, Charanjit S. , Melduni, Rowlens M. , Alsidawi, Said , Rihal, Charanjit S. , Ayoub, Chadi

Mayo Clinic

Echocardiography | June 18, 2019 | Volume: 36 | Issue: 7 | Pages: 1397-1400

10.1111/echo.14403 | PMID 31209920 Get It

AbstractWe describe a case of a mass‐like echocardiographic density on a mechanical prosthetic aortic valve. We initially suspected a thrombus vs vegetation on transthoracic echocardiography, but after transesophageal echocardiography, the density was subsequently determined to be cavitation by reviewing the initial images in slow motion.
Asthma and risk of glioma: a population-based case–control study
Kaur, Harsheen, Ryan, Conor S. , Sheen, Youn Ho, Seol, Hee Yun , Sohn, Sunghwan , Ryu, Euijung , Juhn, Young J. , King, Katherine S. , Juhn, Young, Lachance, Daniel Honore , Wi, Chung‐Il

Mayo Clinic

BMJ Open | June 18, 2019 | Volume: 9 | Issue: 6 | Pages: e025746

10.1136/bmjopen-2018-025746 | PMID 31213444 Get It

Objectives Literature suggests an inconsistent, but largely inverse, association between asthma and risk of glioma, which is primarily due to methodological inconsistency in sampling frame and ascertainment of asthma. The objective of the study was to clarify the association between asthma and risk of glioma by minimising methodological biases (eg, recall and detection bias). Design A population-based case–control study. Setting General population in Olmsted County, Minnesota, USA. Participants All eligible biopsy-proven incident glioma cases (1995–2014) and two sets of controls among residents matched to age and sex (first set: community controls without glioma; second set: MRI-negative controls from the same community). Methods The predetermined asthma criteria via medical record review were applied to ascertain asthma status of cases and controls. History of asthma prior to index date was compared between glioma cases and their matched controls using conditional logistic regression models. Propensity score for asthma status was adjusted for multivariate analysis. Results We enrolled 135 glioma cases (median age at index date: 53 years) and 270 controls. Of the cases, 21 had a history of asthma (16%), compared with 36 of MRI controls (27%) (OR (95% CI) 0.48 (0.26 to 0.91), p=0.03). With MRI controls, an inverse association between asthma and risk of glioma persisted after adjusting for the propensity score for asthma status, but did not reach statistical significance probably due to the lack of statistical power (OR (95% CI) 0.48 (0.21 to 1.09); p=0.08). Based on comparison of characteristics of controls and cases, community controls seem to be more susceptible to a detection bias. Conclusions While differential detection might account for the association between asthma and risk of glioma, asthma may potentially pose a protective effect on risk of glioma. Our study results need to be replicated by a larger study.
DNA repair and cancer in colon and rectum: Novel players in genetic susceptibility
Pardini, Barbara , Corrado, Alda, Berndt, Sonja I. , Brenner, Hermann , Caan, Bette J. , Casey, Graham , Chang‐Claude, Jenny , Gala, Manish , Gallinger, Steven , Haile, Robert W. , Harrison, Tabitha A. , Hayes, Richard B. , Hoffmeister, Michael , Huyghe, Jeroen R. , Jenkins, Mark A. , Lindor, Noralane M. , Nan, Hongmei , Slattery, Martha L. , Vodičková, Ludmila, Vodička, Pavel , Gemignani, Federica , Peters, Ulrike , Naccarati, Alessio , Hoffmeister, Michael , Slattery, Martha L , Jenkins, Mark A , Haile, Robert W , Harrison, Tabitha A , Brenner, Hermann , Hayes, Richard B , Nan, Hongmei , Vodicka, Pavel , Caan, Bette J , Paolicchi, Elisa , Cugliari, Giovanni , Bezieau, Stéphane , Bien, Stephanie A. , Campbell, Peter T. , Chan, Andrew T. , Cotterchio, Michelle , Hopper, John L. , Marchand, Loı̈c Le , Lin, Yi , Newcomb, Polly A. , Ogino, Shuji , Potter, John D. , Schoen, Robert E. , White, Emily E. , Vymetalkova, Veronika Polakova , Landi, Stefano

Mayo Clinic

International Journal of Cancer | June 18, 2019 | Volume: 146 | Issue: 2 | Pages: 363-372

10.1002/ijc.32516 | PMID 31209889 Get It

Interindividual differences in DNA repair systems may play a role in modulating the individual risk of developing colorectal cancer. To better ascertain the role of DNA repair gene polymorphisms on colon and rectal cancer risk individually, we evaluated 15,419 single nucleotide polymorphisms (SNPs) within 185 DNA repair genes using GWAS data from the Colon Cancer Family Registry (CCFR) and the Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO), which included 8,178 colon cancer, 2,936 rectum cancer cases and 14,659 controls. Rs1800734 (in MLH1 gene) was associated with colon cancer risk (p‐value = 3.5 × 10−6) and rs2189517 (in RAD51B) with rectal cancer risk (p‐value = 5.7 × 10−6). The results had statistical significance close to the Bonferroni corrected p‐value of 5.8 × 10−6. Ninety‐four SNPs were significantly associated with colorectal cancer risk after Binomial Sequential Goodness of Fit (BSGoF) procedure and confirmed the relevance of DNA mismatch repair (MMR) and homologous recombination pathways for colon and rectum cancer, respectively. Defects in MMR genes are known to be crucial for familial form of colorectal cancer but our findings suggest that specific genetic variations in MLH1 are important also in the individual predisposition to sporadic colon cancer. Other SNPs associated with the risk of colon cancer (e.g., rs16906252 in MGMT) were found to affect mRNA expression levels in colon transverse and therefore working as possible cis‐eQTL suggesting possible mechanisms of carcinogenesis.
Spontaneous radial artery pseudoaneurysm in an infant due to idiopathic medial hypoplasia – a case report
Kesler, William W. , Maleszewski, Joseph J. , Payatakes, Alexander

Mayo Clinic

Case Reports in Plastic Surgery and Hand Surgery | June 18, 2019 | Volume: 6 | Issue: 1 | Pages: 69-73

10.1080/23320885.2019.1614449 | PMID 31259203 Get It

Induction of chondrogenic or mesenchymal stem cells from human periodontal ligament cells through inhibition of Twist2 or Klf12
Takai, Hideki , Wijnen, André J. van , van Wijnen, Andre J , Ogata, Yorimasa

Mayo Clinic

Journal of Oral Science | June 17, 2019 | Volume: 61 | Issue: 2 | Pages: 313-320

10.2334/josnusd.18-0224 | PMID 31217381 Get It

In older patients with UTIs, deferring or not prescribing antibiotics was linked to adverse outcomes
O’Horo, John C. , Tande, Aaron J. , Tande, Aaron , O'Horo, John C

Mayo Clinic

Annals of Internal Medicine | June 17, 2019 | Volume: 170 | Issue: 12 | Pages: JC70

10.7326/acpj201906180-070 | PMID 31207623 Get It

Pak2 kinase promotes cellular senescence and organismal aging
Lee, Jong-Sun, Mo, Yan , Gan, Haiyun , Burgess, Rebecca J., Baker, Darren J. , Deursen, Jan M. van , Zhang, Zhiguo , Zhang, Zhiguo , Baker, Darren J

Mayo Clinic

Proceedings of the National Academy of Sciences | June 17, 2019 | Volume: 116 | Issue: 27 | Pages: 13311-13319

10.1073/pnas.1903847116 | PMID 31209047 Get It

Cellular senescence defines an irreversible cell growth arrest state linked to loss of tissue function and aging in mammals. This transition from proliferation to senescence is typically characterized by increased expression of the cell-cycle inhibitor p16 INK4a and formation of senescence-associated heterochromatin foci (SAHF). SAHF formation depends on HIRA-mediated nucleosome assembly of histone H3.3, which is regulated by the serine/threonine protein kinase Pak2. However, it is unknown if Pak2 contributes to cellular senescence. Here, we show that depletion of Pak2 delayed oncogene-induced senescence in IMR90 human fibroblasts and oxidative stress–induced senescence of mouse embryonic fibroblasts (MEFs), whereas overexpression of Pak2 accelerated senescence of IMR90 cells. Importantly, depletion of Pak2 in BubR1 progeroid mice attenuated the onset of aging-associated phenotypes and extended life span. Pak2 is required for expression of genes involved in cellular senescence and regulated the deposition of newly synthesized H3.3 onto chromatin in senescent cells. Together, our results demonstrate that Pak2 is an important regulator of cellular senescence and organismal aging, in part through the regulation of gene expression and H3.3 nucleosome assembly.
Identifying the Most Costly Patients in Radiation Oncology and Predicting the Top Spenders
Waddle, Mark R. , Kaleem, Tasneem , Stross, William C. , Malouff, Timothy D. , White, Launia J. , Li, Zhou, Naessens, James M. , Spaulding, Aaron , Keole, Sameer R., Kaleem, Tasneem A, White, Launia, Naessens, James , Keole, Sameer , Spaulding, Aaron , Li, Zhou, Aljabri, Duaa , Daniel, J. , Miller, Robert C.

Mayo Clinic

Journal of Oncology Practice | June 17, 2019 | Volume: 15 | Issue: 8 | Pages: e704-e716

10.1200/jop.18.00627 | PMID 31206338 Get It

PURPOSE: Quality payment programs aim to adjust payments on the basis of quality and cost; however, few quality metrics exist in radiation oncology. This study evaluates and predicts the top spenders (TS) after radiation therapy (RT). MATERIALS AND METHODS: Patient characteristics, cancer details, treatments, toxicity, and survival data were collected for patients treated with RT at Mayo Clinic from 2007 to 2016. Standardized costs were obtained and adjusted for inflation. TSs were identified as those with greater than 93rd percentile costs (≥ $120,812). Prediction models were developed to predict TSs using training and validation sets using information available at consultation, after RT, and at last follow-up. RESULTS: A total of 15,131 patients were included and 1,065 TSs identified. Mean cost overall was $55,290 (median, $39,996) for all patients. Prediction models 1, 2, and 3 had concordance statistics of 0.83 to 0.83, 0.85 to 0.85, and 0.87 to 0.88, respectively in training and validation, indicating excellent prediction of TSs. Factors that were most predictive of TSs included stage N/A and stage 4 ( v stage 0; odds ratio [OR], 18.23 and 8.44, respectively; P < .001); hematologic, upper GI, skin and lung cancers ( v breast; OR, 11.45, 7.69, 3.81, and 2.43, respectively; P < .01); immunotherapy, surgery, and chemotherapy use (OR, 4.36, 2.51, and 1.61, respectively; P < .01); hospitalizations within 90 days of RT (OR, 2.26; P < .01); or death during the episode (OR, 1.56; P < .01). CONCLUSION: This is the first study of its kind to predict with high accuracy the highest spenders in radiation oncology. These patients may benefit from pre-emptive management to mitigate costs, or may require exclusion or adjustment from quality payment programs.